

Hep B Vaccine–Rheumatoid Arthritis Link Denied

BY MIRIAM E. TUCKER
Senior Writer

BALTIMORE — The hepatitis B vaccine does not appear to be associated with an increased risk for rheumatoid arthritis, Dr. Roger P. Baxter and his associates reported at a vaccine research conference sponsored by the National Foundation for Infectious Diseases.

Both acute and chronic arthropathies have been reported in adults vaccinated with the tetanus-diphtheria (Td), hepatitis B (HepB), and measles-mumps-rubella (MMR) vaccines.

However, most of the evidence to support or refute a causal relationship between the Td or HepB vaccine and chron-



'These data would imply that hepatitis B vaccine would only contribute to a small minority of cases.'

DR. BAXTER

ic arthritis has come from isolated case reports, uncontrolled observational studies, or studies that lacked sufficient statistical power, said Dr. Baxter, associate director of the Vaccine Study Center at Kaiser Permanente, Oakland, Calif., and his associates.

A case-control analysis designed to overcome the shortcomings of the previous studies included a cohort of continuous enrollees in Northern California Kaiser Permanente's health plan from Jan. 1, 1995, through Dec. 31, 1999, who were aged 15-59 years during Jan. 1, 1997-Dec. 31, 1999.

Individuals who had made clinic visits for rheumatoid arthritis (RA) and other inflammatory conditions prior to their follow-up start date were excluded.

A total of 416 incident cases of RA were identified (based on definitive diagnosis at the time or subsequent assessment by a rheumatologist), and each was matched with three controls based on age and the number of clinic visits made during the year prior to the onset date.

Rates of hepatitis B vaccination among the RA patients were compared with those of controls, with adjustment for sex, age, and exact number of clinic visits. Similar comparisons were made for the tetanus and influenza vaccines.

No statistically significant risk of RA was found for any of the three vaccines. Only 1% of RA patients versus 0.6% of controls had been exposed to the hepatitis B vaccine within 1-90 days of onset of RA symptoms, for an adjusted odds ratio of 1.48.

Within 1-180 days, the percentages were 1.9% with RA versus 0.9% of controls, giving a still insignificant odds ratio of 2.01. Within 1 year, 2.4% of RA cases and 1.6% of controls had been exposed to the vaccine, again insignificant at 1.42.

In all, only 10 of the 416 RA patients had received the HepB vaccine within 1 year of symptom onset, suggesting that "if

there is an association, these data would imply that hepatitis B vaccine would only contribute to a small minority of cases," Dr. Baxter and his associates said in their poster.

Results for the other two vaccines were also not significant, with adjusted odds ratios of 0.77-1.06 for tetanus and 0.66-1.11 for influenza.

Health care utilization was higher among those with RA, which was a slight confounder in this study despite the at-

tempt to control for number of visits: Even after adjustment, there was still a significant residual effect for number of visits, with an odds ratio of 1.15.

"Basically, people who get vaccines of all kinds are different from those who don't, and underlying differences may confound the relationship with things like RA. We try to control for these factors by matching and analyses, but still we think there are differences. ... People who have RA are more likely to be higher utilizers and also

more likely to have gotten vaccines than people who don't utilize the system as much," Dr. Baxter said in a follow-up interview.

However, he added, although the difference in utilization was statistically significant, it probably wasn't that different clinically. "We thought initially this was an important confounder. But in the end we found that although they were different, in reality we could adjust for the vast majority of the difference." ■

CALLING ALL ADOLESCENTS AND ADULTS



A CALL TO ARMS
AGAINST PERTUSSIS

Pertussis protection for both adolescents and adults 11 through 64 years of age

Adacel[®]
Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular
Pertussis Vaccine Adsorbed
Arming More People Against Pertussis



Safety Information

ADACEL vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 11 through 64 years of age.

As with any vaccine, ADACEL vaccine may not protect 100% of vaccinated individuals. There are risks associated with all vaccines. The most common injection site adverse events include pain, erythema, and swelling. The most common systemic adverse events include headache, body ache, tiredness, and fever. ADACEL vaccine is contraindicated in persons with known systemic hypersensitivity to any component of the vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with the diphtheria, tetanus, or pertussis components found in ADACEL vaccine should be carried out. Because any intramuscular injection can cause injection site hematoma, ADACEL vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer ADACEL vaccine to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection.

Before administering ADACEL vaccine, please see brief summary of full Prescribing Information on following page.

ADACEL vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

To order ADACEL vaccine, log onto www.vaccineshoppe.com or call 1-800-VACCINE (1-800-822-2463)

Learn about pertussis disease and prevention at www.ADACELVACCINE.com

References:

1. Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. *MMWR*. 2006;55(RR-17):21-22. 2. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the ACIP. *MMWR*. 2006;55(RR-3):22.

* Advisory Committee on Immunization Practices. † Tetanus, diphtheria, and acellular pertussis. ‡ 19-64 years of age. § 11-18 years of age.

sanofi pasteur. Discovery Drive, Swiftwater, Pennsylvania 18370. www.sanofipasteur.us
MKT12997 © 2007 Sanofi Pasteur Inc. 2/07 Printed in USA

sanofi pasteur
The vaccines business of sanofi-aventis Group